Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine

[1]  S. Sanche,et al.  Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. , 2007, Experimental hematology.

[2]  M. Lübbert,et al.  Superiority of prolonged low‐dose azanucleoside administration? , 2006, Cancer.

[3]  M. Fraga,et al.  The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. , 2006, Blood.

[4]  Peter A. Jones,et al.  Zebularine: A Unique Molecule for an Epigenetically Based Strategy in Cancer Chemotherapy , 2005, Annals of the New York Academy of Sciences.

[5]  R. Momparler.  Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). , 2005, Seminars in hematology.

[6]  Alexander V. Lyubimov,et al.  Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine , 2005, Clinical Cancer Research.

[7]  M. Bernstein,et al.  Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia , 2005, Anti-cancer drugs.

[8]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[9]  Peter A. Jones,et al.  Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells , 2004, Molecular and Cellular Biology.

[10]  J. Laliberté,et al.  Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase , 2004, Cancer Chemotherapy and Pharmacology.

[11]  Wei Ye,et al.  Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.

[12]  Lei Zhou,et al.  Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. , 2002, Journal of molecular biology.

[13]  R. Wolfenden,et al.  Substrate connectivity effects in the transition state for cytidine deaminase. , 1998, Biochemistry.

[14]  R. Momparler,et al.  Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells , 1998, Cancer Chemotherapy and Pharmacology.

[15]  K. Bélanger,et al.  Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.

[16]  S. Côté,et al.  Pharmacological approach for optimization of the dose schedule of 5-Aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia , 1997, Leukemia.

[17]  N. Eliopoulos,et al.  Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. , 1996, Cancer gene therapy.

[18]  R. Wolfenden,et al.  Binding of pyrimidin-2-one ribonucleoside by cytidine deaminase as the transition-state analogue 3,4-dihydrouridine and the contribution of the 4-hydroxyl group to its binding affinity. , 1989, Biochemistry.

[19]  N. Onetto,et al.  In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine. , 1987, Seminars in oncology.

[20]  R. Momparler,et al.  Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. , 1983, Biochemical pharmacology.

[21]  D. Ho.  Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse. , 1973, Cancer research.